The presence of an ASXL1 mutation in the absence of a favorable-risk AML subtype places the patient in the adverse genetic risk category according to the ELN risk classification7, thereby influencing treatment decisions. This evidence concerns the gene ASXL1 and acute myeloid leukemia.